25 results for “apoe2”. Showing 25 of 39,449.
APOE2 gene therapy reduces amyloid deposition, and improves markers of neuroinflammation and neurodegeneration in a mouse model of Alzheimer disease.
APOE2 via a gene therapy approach which bathes the entire
iPSC-derived blood-brain barrier modeling reveals APOE isoform-dependent interactions with amyloid beta.
APOE2, APOE3, and APOE4 - hold varying significance in Alzheimer's Disease
APOE4 Increases Energy Metabolism in APOE-Isogenic iPSC-Derived Neurons.
APOE2 is known to lower the AD risk, while APOE3
Protective ApoE variants support neuronal function by effluxing oxidized phospholipids.
ApoE2 and ApoE3 Christchurch (ApoE3Ch) confer resistance to disease, yet little
APOE genotype determines cell-type-specific pathological landscape of Alzheimer's disease.
APOE2 decreasing it compared with the common APOE3 allele. Using
Protection against Alzheimer’s Disease with APOE Christchurch Variant — How?
APOE2 homozygosity as compared with the general population.2-4 APOE2 heterozygosity
Decreased lipidated ApoE-receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes.
ApoE2 (lipApoE2) avoids LDLR recycling defects observed with lipApoE3/E4 and decreases
Lipidome and proteome of astrocyte and microglia ApoE lipoprotein reveal differences based on cell type and ApoE isoform.
APOE2, APOE3, and APOE4. APOE4 is the strongest genetic risk
Decreased lipidated ApoE-receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes.
ApoE2 (lipApoE2) avoids LDLR recycling defects observed with lipApoE3/E4 and decreases
Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders.
ApoE2 and apoE4 increase the risk for heart disease: apoE2
AAVrh.10 delivery of novel APOE2-Christchurch variant suppresses amyloid and Tau pathology in Alzheimer's disease mice.
APOE2 allele with the Christchurch mutation (R136S) (E2Ch) will provide
APOE gene variants in primary dyslipidemia.
apoE2 is associated with a mild decrease in LDL-cholesterol
Apolipoprotein E isoform-dependent microglia migration.
apoE2), ε3 (apoE3), or ε4 (apoE4) allele of APOE
APOE gene variants in primary dyslipidemia.
apoE2 is associated with a mild decrease in LDL-cholesterol
APOE2: protective mechanism and therapeutic implications for Alzheimer's disease.
designed to leverage the protective effect of APOE2 to treat AD.
Alzheimer's Risk Factors Age, APOE Genotype, and Sex Drive Distinct Molecular Pathways.
apoE2-, apoE3-, and apoE4-targeted replacement mice across young, middle
Central Nervous System Lipoproteins: ApoE and Regulation of Cholesterol Metabolism.
apoE2 and apoE3, apoE4 has markedly altered CNS metabolism, is associated
Astrocyte-secreted glypican-4 drives APOE4-dependent tau hyperphosphorylation.
APOE2, considered to be a protective allele to AD, and second
APP-Induced Patterned Neurodegeneration Is Exacerbated by APOE4 in Caenorhabditis elegans.
APOE2 and APOE3), the ε4 allele of APOE (APOE4) hastens
Structural and functional insights into naturally occurring apolipoprotein E variants with protective effects against Alzheimer's disease.
apoE2, apoE3 and apoE4. APOE4 is the strongest genetic risk
Pathways to Alzheimer's Disease: The Intersecting Roles of Clusterin and Apolipoprotein E in Amyloid-β Regulation and Neuronal Health.
APOE2, APOE3, and APOE4. Notably, the APOE4 allele substantially increases
Apolipoprotein E regulates lipid metabolism and α-synuclein pathology in human iPSC-derived cerebral organoids.
apoE2 and apoE3, but not apoE4. Lipidomics analysis detects the increased
Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist.
APOE2 decreases risk relative to APOE3. In the P301S mouse
From Genetics to Neuroinflammation: The Impact of ApoE4 on Microglial Function in Alzheimer's Disease.
ApoE2 and ApoE3. ApoE4's unique structure, which arises from
APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches.
APOE2 isoforms, but translation to human clinical trials has proven